- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05601505
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer (CINTS-R)
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer --- a Multicenter Randomized Controlled Trial (CINTS-R)
Study Overview
Status
Intervention / Treatment
Detailed Description
Rectal cancer still remains one of the most popular tumors, a multidisciplinary approach including neoadjuvant chemoradiotherapy, total mesorectal excision and adjuvant chemotherapy has resulted a satisfying oncologic outcome in terms of reducing local recurrence and improving local control of disease for the treatment of rectal cancer, however, distance metastasis still remains as high as 30% and the long-term survival outcomes is still unsatisfying.
The recent conception of total neoadjuvant therapy and immune therapy is becoming popular and the oncologic effects are encouraging, especially in terms of circulating tumor DNA (ctDNA), the prognostic value of ctDNA has been demonstrated by our prior study. This study demonstrated that ctDNA is an effective marker of tumor burden in real time and for the first time identified baseline ctDNA mutation frequency before nCRT as an independent prognostic factor for recent LARC recurrence and metastasis. This suggests that patients with different tumor burden according to baseline ctDNA mutation frequency should be given neoadjuvant therapy with corresponding intensity, in order to improve systemic disease control in patients with high risk of recurrence and metastasis, and to avoid overtreatment in patients with low risk.
In conclusion, this study will carry out accurate ctDNA-guided neoadjuvant therapy on the basis of previous studies of the research group, and give appropriate treatment plans and treatment intensity to patients with different disease degrees. At the same time, combined with the latest progress in clinical diagnosis and treatment, the potential beneficiaries of immunotherapy were screened scientifically, and the combined immunetherapy was implemented accordingly. With the development of this study, several precision medicine research results obtained by our research group will be expected to be translated into clinical practice as soon as possible, which will improve the efficacy of LARC patients, reduce the rate of adverse reactions, and ultimately promote the improvement of the treatment level of rectal cancer and the more reasonable use of public medical resources.
The patients with locally advanced rectal cancer staged as cT3-4N0/cTanyN+ will be included in this study. Patients will be randomized into two groups, the treatment group will receive different strategies after next generation sequencing of tumor tissue and IMC, those with MSI-H or TMB-H or POLE/PLOD1 mutation will be advised to receive immune therapy following neoadjuvant chemoradiotherapy (NCRT), and the others will be arranged to randomly receive NCRT (VAF<0.4%) or total neoadjuvant therapy (TNT) (VAF>0.4%) according to the VAF value of ctDNA; the control group will receive NCRT only.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Lin guole, doctor
- Phone Number: 13801081483
- Email: linguole@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100005
- Recruiting
- Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences,
-
Contact:
- Lin guole, doctor
- Phone Number: 13801081483
- Email: linguole@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18-75 years;
- ECOG score 0-2;
- Rectal adenocarcinoma confirmed by pathology;
- The lower margin of the tumor was less than 12cm from the anal margin;
- Patients with clinical stage cT3-4N0M0 or cTanyN+M0;
- Newly treated patients who have not received treatment including radiotherapy, chemotherapy and surgery;
- Liver, kidney and other organs have good function and can tolerate radiotherapy, chemotherapy and surgery;
- Patients and family members can understand the study protocol, voluntarily participate in the study and sign informed consent.
Exclusion Criteria:
- ECOG score > 2;
- Patients with multiple primary colorectal cancers;
- A history of other malignant tumors (other than cured basal cell carcinoma, cervical carcinoma in situ, surgically treated localized prostate cancer, or surgically resected breast ductal carcinoma in situ) within the past 5 years;
- Complicated with intestinal obstruction, intestinal perforation, gastrointestinal bleeding and other patients requiring emergency surgery;
- pregnant or lactating women;
- Patients with a history of severe mental illness, immune disease, hormone medication;
- Patients contraindicated by MRI examination, chemoradiotherapy, immunotherapy or surgery;
- Participated in other clinical researchers in the past 3 months;
- Any other circumstances that the investigator considers inappropriate for inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Traditional neoadjuvant chemoradiotherapy group
Eligible patients randomized into arm A will receive traditional neoadjuvant chemoradiotherapy, including long-course radiotherapy with a total number of 45-50.4Gy in 25-28 fractions, and with concurrent 3 times of oral capecitabine, the strategies of capecitabine are: During radiotherapy: capecitabine 1650mg/m2/d, orally administered twice a day, d1-d14, every 3 weeks as a course; During the non-radiotherapy period: capecitabine 2000mg/m2/d, orally administered twice daily, d1-d14, every 3 weeks as a course |
|
Experimental: ctDNA-guided neoadjuvant treatment group
After sequencing tumor tissue, those with MSI-H/TMB-H or POLD/POLE2 mutation willed be arranged to receive immune therapy following NCRT,Terelizumab,200mg. The others are arranged to randomly receive TNT (VAF>0.4%) or NCRT (VAF<0.4%) according to VAF value by the level of ctDNA. TNT: Long course radiotherapy combined with 2 courses of single-agent capecitabine chemotherapy → 6 courses of CapeOX (Capecitabine 2000mg/m2/ day, twice orally, d1-14; Oxaliplatin 100-130mg/m2, intravenous infusion, d1; Every 3 weeks for a course of treatment.) chemotherapy was performed 2 to 3 weeks after the end of chemotherapy. |
This study will further testify the prognostic value of ctDNA in the treatment term of locally advanced rectal cancer, the higher the VAF value, the higher the risk of recurrence and metastasis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease-related treatment failure, DrTF
Time Frame: 2 years
|
Refers to the time from the start of treatment to the first interruption of treatment Reasons for treatment interruption include tumor progression, adverse effects, patient selection, and death events |
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to recurrence, TTR
Time Frame: 2 years
|
The median time from randomization to the first observation of recurrence.
|
2 years
|
overall survival, 2yOS
Time Frame: 2 years
|
Refers to the proportion of patients still alive at 2 years after surgery
|
2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-PUMCH-C-005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Circulating Tumor DNA
-
Fudan UniversityRecruiting
-
Foundation MedicineJohns Hopkins University; Memorial Sloan Kettering Cancer Center; University... and other collaboratorsCompletedNeoplasms | Cancer | Circulating Tumor DNA | Genomic Testing | Genomic AlterationsUnited States
-
Shanghai Pulmonary Hospital, Shanghai, ChinaUnknownCirculating Tumor DNA | Advanced NSCLC | Circulating Tumor Cells
-
University Hospital, RouenUnknownDetection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. (CTC-Pancreas)Pancreatic Adenocarcinoma | Circulating Tumor Cells | Circulating Tumor DNA (KRAS) | CA 19.9France
-
Assistance Publique - Hôpitaux de ParisUnknownTo Compare the Monitoring of Circulating Tumor DNA With the Efficacy of Chemotherapy Evaluated by Computer Tomography Scan.France
-
Rigshospitalet, DenmarkUnknownWHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC (WHENII)Non Small Cell Lung Cancer | Circulating Tumor Cell | Circulating Tumor DNADenmark
-
MiCareo Taiwan Co., Ltd.CompletedCirculating Tumor Cells (CTCs)Taiwan
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; ScreenCell; Celen... and other collaboratorsUnknownMelanoma | Circulating Tumor CellFrance
-
Fudan UniversityNot yet recruitingColorectal Cancer | Circulating Tumor Cell
-
Zhongnan HospitalUnknownCirculating Tumor CellChina
Clinical Trials on circulating tumor DNA
-
Zhujiang HospitalNot yet recruitingRecurrence | Hepatocellular Carcinoma | Surgery | Circulating Tumor CellChina
-
Christer EricssonKarolinska Institutet; iCellate MedicalUnknownCancer | Neoplasms, Unknown PrimarySweden
-
Zhujiang HospitalRecruitingHepatocellular Carcinoma ResectableChina
-
Rigshospitalet, DenmarkRecruitingGastric Cancer | Esophageal CancerDenmark
-
Helsinki University Central HospitalInstitute for Molecular MedicineUnknown
-
Fudan UniversityRecruiting
-
University Medical Center Ho Chi Minh City (UMC)RecruitingGastric Cancer | Circulating Tumor DNA (ctDNA)Vietnam
-
British Columbia Cancer AgencyUniversity of British Columbia; University of Utah; Pathway Genomics; Boreal GenomicsCompleted
-
Centre Henri BecquerelNot yet recruitingSquamous Cell Carcinoma of the Oral CavityFrance
-
University Hospital, RouenNot yet recruiting